Glaucocalyxin B Alleviates Lipopolysaccharide-Induced Parkinson’s Disease by Inhibiting TLR/NF-κB and Activating Nrf2/HO-1 Pathway

Glaucocalyxin B Alleviates Lipopolysaccharide-Induced Parkinson’s Disease by Inhibiting TLR/NF-κB and Activating Nrf2/HO-1 Pathway

Background/Aims: Parkinson’s disease (PD) is a common neurodegenerative disease in the old population, characterized by dopaminergic neuron loss, inflammation and oxidative stress injury in the substantia nigra. Glaucocalyxin B (GLB), an ent-kauranoid diterpenoid isolated from Rabdosia japonica, has...

Full description

Bibliographic Details
Main Authors: Wei Xu, Deyu Zheng, Yuanyuan Liu, Ji Li, Li Yang, Xiuli Shang
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2017-12-01
Series:Cellular Physiology and Biochemistry
Subjects:
Parkinson’s disease
Glaucocalyxin B
Toll-like receptor
Nuclear factor kappa B
Nuclear factor erythroid 2-related factor 2
Online Access:https://www.karger.com/Article/FullText/485947

Internet

https://www.karger.com/Article/FullText/485947

Similar Items